{"id":206405,"date":"2018-04-14T11:21:02","date_gmt":"2018-04-14T11:21:02","guid":{"rendered":"http:\/\/www.abnewswire.com\/pressreleases\/?p=206405"},"modified":"2018-04-14T11:21:02","modified_gmt":"2018-04-14T11:21:02","slug":"global-drug-eluting-stents-market-to-surpass-usd-95-bn-by-2025","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/global-drug-eluting-stents-market-to-surpass-usd-95-bn-by-2025_206405.html","title":{"rendered":"Global Drug Eluting Stents Market to Surpass USD 9.5 Bn by 2025"},"content":{"rendered":"
\"\"<\/a><\/p>\n
\n
“Bekryl Industry Research “Drug Eluting Stents Market Report””<\/div>\n<\/div>\n<\/div>\n
Worldwide drug eluting stents market is projected to reach over USD 9.5 Billion by 2025 with major five players accounting for over 85% of global share in 2017. <\/div>\n

The Global Drug Eluting Stents Market Value <\/strong>to exceed USD 9.5 Billion by 2025, registering a CAGR of 5.9%. These stents have gained wide scale penetration in last five years owing to regulatory process along with growing prevalence of cardiovascular disease.<\/p>\n

As of 2018, the major five players accounted for over 85% of global share – leading to higher consolidation. Major players are emphasizing on product development to ensure sustainability towards business growth. For instance, in 2017, Medtronic plc launched Resolute Onyx DES in United States post approval from FDA. In the same year, another leading market player– Elixir Medical – introduced new drug eluting stents -“Dynamx”.<\/strong><\/p>\n

Download Drug Eluting Stents Industry Report Sample: <\/strong>https:\/\/bekryl.com\/sample\/sample-request?bekryl=Get-Drug-Eluting-Stents-Sample-Report.<\/a><\/p>\n

Bekryl’s market research report, Global Drug Eluting Stents Market Size Analysis and Industry Opportunity, finds North America to account for 43% of global sales in 2018. Presence of good medical coverage, well reached distribution channel, and high number of specialized healthcare specialists are key factors creating favorable business environment in the region. In terms of revenue, Europe drug eluting stents industry stands next to North America. Germany, UK, and France collectively accounted for over 65% of Europe share.<\/p>\n

Some key trends from the global Drug Eluting Stents market:<\/p>\n

Trend#1: By Type, Microporous Surface Stent to Account for 48% of Global Share<\/strong><\/p>\n

Government subsidies along with pricing cap will create favorable market for overall sales of microporous surface stent worldwide. According to World Health Organization (WHO), CVD is the leading cause of death worldwide, representing nearly 31% of global deaths.<\/p>\n

Trend#2: By Therapeutic Applications, Coronary Artery Disease to Account for 57% of Global Share<\/strong><\/p>\n

Coronary artery disease will account for over 57% of global share in 2018. These stents are highly standardized with safety features and as such, its prominence has increased over other conventional approach.<\/p>\n

To know more about industry related insights and report access, visit: <\/strong>https:\/\/bekryl.com\/industry-trends\/drug-eluting-stents-market-size-analysis<\/a><\/p>\n

Some key global Drug Eluting Stents Market Players<\/strong> are Biosensors International Group, CARDIONOVUM GmbH, KYOTO MEDICAL PLANNING Co., Ltd., Boston Scientific Corporation, Terumo Medical Corporation, Cook Medical, Abbott Vascular Inc., AlviMedica Medical Technologies Inc., Medtronic, Inc., Abbott Laboratories, HangZhou HuaAn Biotechnology Co.,Ltd, XTENT, Inc., Shandong JW Medical Systems, Stentys, Biotronik, Lepu Medical Technology, Amaranth Medical, Inc..<\/p>\n

Research Scope<\/strong><\/p>\n

By Therapeutic Application:<\/p>\n